Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00399763 · ClinicalTrials.gov registry record · NA

Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

A NA study of Attention Deficit Hyperactivity Disorder and Substance Abuse, sponsored by Denver Health and Hospital Authority.

Completed
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT00399763: Completed NA study of Attention Deficit Hyperactivity Disorder and Substance Abuse, sponsored by Denver Health and Hospital Authority.

NCT00399763 is a NA study of Attention Deficit Hyperactivity Disorder and Substance Abuse that has completed, run by Denver Health and Hospital Authority. The registered enrollment target is 70 participants, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00399763, a NA study of Attention Deficit Hyperactivity Disorder and Substance Abuse, has completed, sponsored by Denver Health and Hospital Authority.

COMPLETED
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out whether atomoxetine (also called Strattera) helps teenagers (12-19) with Attention Deficit Hyperactivity Disorder (ADHD) and drug/alcohol problems.

Primary Outcome

All 18 ADHD symptoms are rated on a scale of 0 (none) to 3 (severe) since the previous study visit. The scores are summed to create a total ADHD severity scale score ranging from 0 (none) to 54 (most severe). A single value of mean change in ADHD severity for each group (placebo and atomoxetine) was calculated using linear mixed models in an intent-to-treat an analysis.

Interventions

  • DRUG Placebo
  • DRUG Atomoxetine

Study Locations (1)

Colorado

  • Denver Health Medical Center - Denver

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2005-09
Est. Completion 2008-02
Phase NA

What the finished NCT00399763 record still lists

NCT00399763 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (68% lower).

The record links to 2 conditions, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00399763 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT00399763 about?

NCT00399763 is a clinical study titled "Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder". The purpose of this study is to find out whether atomoxetine (also called Strattera) helps teenagers (12-19) with Attention Deficit Hyperactivity Disorder (ADHD) and drug/alcohol problems.

What is the current status of trial NCT00399763?

This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2005-09. Estimated completion is 2008-02.

What conditions does trial NCT00399763 study?

This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder, Substance Abuse.

What interventions are being tested in trial NCT00399763?

The interventions under investigation include: Placebo (DRUG), Atomoxetine (DRUG).

Who is sponsoring clinical trial NCT00399763?

This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00399763 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Attention Deficit Hyperactivity Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00399763's enrollment target sits among peer trials

70 53rd of 102 higher than 50 of 102 other Attention Deficit Hyperactivity Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00399763, the US trial registry maintained by the National Library of Medicine. NCT00399763 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.